NasdaqGS:CLVS

Stock Analysis Report

Executive Summary

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally.

Snowflake

Fundamentals

High growth potential and slightly overvalued.

Risks

  • Clovis Oncology has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Clovis Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.2%

NasdaqGS:CLVS

1.7%

US Biotechs

2.1%

US Market


1 Year Return

-83.2%

NasdaqGS:CLVS

-9.1%

US Biotechs

-0.04%

US Market

CLVS underperformed the Biotechs industry which returned -8.8% over the past year.

CLVS underperformed the Market in United States of America which returned 0.2% over the past year.


Share holder returns

CLVSIndustryMarket
7 Day5.2%1.7%2.1%
30 Day-46.8%0.7%-3.2%
90 Day-64.8%2.4%2.8%
1 Year-83.2%-83.2%-8.3%-9.1%2.2%-0.04%
3 Year-74.6%-74.6%11.9%8.1%41.5%32.3%
5 Year-87.6%-87.6%5.2%0.3%55.0%37.8%

Price Volatility Vs. Market

How volatile is Clovis Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clovis Oncology undervalued based on future cash flows and its price relative to the stock market?

46%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Clovis Oncology's share price is below the future cash flow value, and at a moderate discount (> 20%).

Clovis Oncology's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Clovis Oncology is loss making, we can't compare its value to the US Biotechs industry average.

Clovis Oncology is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Clovis Oncology, we can't assess if its growth is good value.


Price Based on Value of Assets

Clovis Oncology has negative assets, we can't compare the value of its assets to the US Biotechs industry average.


Next Steps

Future Growth

How is Clovis Oncology expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

39.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Clovis Oncology's revenue is expected to grow significantly at over 20% yearly.

Clovis Oncology's earnings are expected to grow significantly at over 20% yearly.

Clovis Oncology's revenue growth is expected to exceed the United States of America market average.

Clovis Oncology's earnings growth is expected to exceed the United States of America market average.

Clovis Oncology's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Clovis Oncology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Clovis Oncology performed over the past 5 years?

-13.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Clovis Oncology does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Clovis Oncology's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Clovis Oncology's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Clovis Oncology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Clovis Oncology has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Clovis Oncology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Clovis Oncology's financial position?


Financial Position Analysis

Clovis Oncology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Clovis Oncology's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Clovis Oncology has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Clovis Oncology's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Clovis Oncology has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Clovis Oncology has less than a year of cash runway based on current free cash flow.

Clovis Oncology has less than a year of cash runway if free cash flow continues to grow at historical rates of 17.2% each year.


Next Steps

Dividend

What is Clovis Oncology's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Clovis Oncology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Clovis Oncology's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Clovis Oncology has not reported any payouts.

Unable to verify if Clovis Oncology's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Clovis Oncology has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Clovis Oncology's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Clovis Oncology's salary, the management and board of directors tenure and is there insider trading?

3.6yrs

Average management tenure


CEO

Patrick Mahaffy (56yo)

10.3yrs

Tenure

US$6,267,458

Compensation

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. on April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic ...


CEO Compensation Analysis

Patrick's remuneration is higher than average for companies of similar size in United States of America.

Patrick's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.6yrs

Average Tenure

55yo

Average Age

The tenure for the Clovis Oncology management team is about average.


Board Age and Tenure

10.3yrs

Average Tenure

63yo

Average Age

The average tenure for the Clovis Oncology board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

More shares have been bought than sold by Clovis Oncology individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$233,40021 Aug 19
James Blair
EntityIndividual
Role
Member of the Board of Directors
Director
Shares40,000
Max PriceUS$5.97
BuyUS$279,57619 Aug 19
Patrick Mahaffy
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares50,000
Max PriceUS$5.61
BuyUS$48,76216 Aug 19
Thorlef Spickschen
EntityIndividual
Role
Member of the Board of Directors
Director
Shares8,600
Max PriceUS$5.67
BuyUS$50,23215 Aug 19
Thorlef Spickschen
EntityIndividual
Role
Member of the Board of Directors
Director
Shares9,200
Max PriceUS$5.46
SellUS$473,98618 Mar 19
Domain Associates, L.L.C.
EntityCompany
Shares17,056
Max PriceUS$27.79
BuyUS$54,06708 Mar 19
Armistice Capital LLC
EntityCompany
Shares1,920
Max PriceUS$28.16
SellUS$1,647,66008 Mar 19
Armistice Capital LLC
EntityCompany
Shares2,240,920
Max PriceUS$31.92

Ownership Breakdown


Management Team

  • Dan Muehl (55yo)

    Executive VP & CFO

    • Tenure: 3.4yrs
    • Compensation: US$1.51m
  • Patrick Mahaffy (56yo)

    Co-Founder

    • Tenure: 10.3yrs
    • Compensation: US$6.27m
  • Gillian Ivers-Read (65yo)

    Co-Founder

    • Tenure: 10.3yrs
    • Compensation: US$1.76m
  • Anna Sussman

    Vice President of Investor Relations

    • Tenure: 0.0yrs
  • Paul Gross (54yo)

    Chief Compliance Officer

    • Tenure: 3.6yrs
  • Ann Bozeman

    Executive Vice President of Human Resources

    • Tenure: 2.9yrs
  • Breanna Burkart

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 2.9yrs
  • Lindsey Rolfe (51yo)

    Executive VP of Clinical

    • Tenure: 4.0yrs
    • Compensation: US$1.82m

Board Members

  • Paul Klingenstein (63yo)

    Director

    • Tenure: 10.3yrs
    • Compensation: US$359.98k
  • Brian Atwood (66yo)

    Director

    • Tenure: 10.6yrs
    • Compensation: US$364.98k
  • Ed McKinley (67yo)

    Director

    • Tenure: 10.6yrs
    • Compensation: US$369.98k
  • Jim Blair (79yo)

    Director

    • Tenure: 10.6yrs
    • Compensation: US$369.98k
  • Ginger Graham (63yo)

    Chairman

    • Tenure: 0.2yrs
    • Compensation: US$357.48k
  • Patrick Mahaffy (56yo)

    Co-Founder

    • Tenure: 10.3yrs
    • Compensation: US$6.27m
  • Thorlef Spickschen (78yo)

    Director

    • Tenure: 10.6yrs
    • Compensation: US$357.48k
  • Keith Flaherty (48yo)

    Director

    • Tenure: 6.6yrs
    • Compensation: US$354.98k
  • Rick Fair (50yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$539.35k

Company Information

Clovis Oncology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clovis Oncology, Inc.
  • Ticker: CLVS
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$321.927m
  • Shares outstanding: 54.66m
  • Website: https://www.clovisoncology.com

Number of Employees


Location

  • Clovis Oncology, Inc.
  • 5500 Flatiron Parkway
  • Suite 100
  • Boulder
  • Colorado
  • 80301
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLVSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2011
C6ODB (Deutsche Boerse AG)YesCommon StockDEEURNov 2011

Biography

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offer ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/23 00:17
End of Day Share Price2019/08/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.